MedTrace Logo

A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden

NCT03328364 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 211

Last updated 2024-11-21

No results posted yet for this study

Summary

The purpose of this study is to provide real world data on treatment with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients.

The primary purpose is to evaluate overall survival (OS) in mCRPC patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel) (post chemo patients).

This study will also evaluate treatment duration with enzalutamide in patients pre- and post-chemo.

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

enzalutamide

oral

DRUG

docetaxel

intravenous infusion

Sponsors & Collaborators

  • Astellas Pharma a/s

    lead INDUSTRY

Principal Investigators

  • Medical Scientific Advisor · Astellas Pharma a/s

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2017-12-24
Completion
2017-12-24

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03328364 on ClinicalTrials.gov